Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®

Summary

This is a post-marketing real-world study designed to evaluate the efficacy and safety of Tabellvi® (Adalimumab Injection) in Chinese adult subjects with moderate to severe active Crohn's disease via a single-arm trial. A total of 50 subjects are planned to be enrolled. The primary endpoints include the incidence rates of adverse events (AEs), serious adverse events (SAEs), adverse drug reactions (ADRs) and serious ADRs, as well as the proportion of subjects achieving clinical remission (CDAI score \< 150) at Week 26.

Timeline

Start

2026-08

Primary completion

2028-12

Completion

2029-03

Drugs

Indications